3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
6
Neoplasms by Site
2
Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer Not Immediately Operated
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Interventions
X-Rays
7
Phantoms, Imaging
7
Magnetic Resonance Spectroscopy
7
Specimen Handling
6
Nuclear Medicine Department, Hospital
5
Biopsy
4
tazemetostat
3
Cyclophosphamide
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Vincristine
2
Topotecan
2
Methotrexate
2
LY3023414
2
Etoposide
2
Cisplatin
2
Carboplatin
2
talazoparib
1
selinexor
1
pembrolizumab
1
olaparib
1
irinotecan sucrosofate
1
fludarabine phosphate
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Rhabdoid Tumor
×
ribociclib
×
90 days
×
Clear all
No trials found.